ArticleBlood cancer journal2022
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.Blood advances · 2026Guideline
- Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management.European journal of haematology · 2026Review
- Apolipoprotein A-IV Cardiac Amyloidosis: Beyond ATTR and AL.JACC. Case reports · 2026Article
- A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging.The Journal of clinical investigation · 2026Article
- Article
- Monoclonal gammopathy exclusion in transthyretin amyloid cardiomyopathy: iStopMM estimated glomerular filtration rate-adjusted serum-free light chain ratio cut-offs.European heart journal · 2026Article
- The light chain hunt: appraising assays in AL amyloidosis.Blood advances · 2026Article
- C3 Glomerulopathy With Occult Gammopathy Treated With Low-Dose, Fixed Duration Venetoclax.Kidney international reports · 2026Article
- Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance.Clinical kidney journal · 2026Review
- Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.British journal of haematology · 2026Review
- Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification.Blood cancer journal · 2026Article
- Proving Bone Marrow Plasma Cell Clonality by Flow Cytometry: An Important Tool in the Diagnosis of Immunoglobulin Light-Chain Amyloidosis.Biomedicines · 2025Article
- Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS.Blood advances · 2025Article
- Management recommendations for kidney transplantation in patients with plasma cell dyscrasia.Kidney international · 2025Review
- Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance.Blood cancer journal · 2025Article
- Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations.Journal of clinical medicine · 2025Review
- Cardiac Amyloidosis: Tribulations and New Frontiers.Journal of personalized medicine · 2025Review
- Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.JACC. CardioOncology · 2025Article
- Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis.EBioMedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 4 countries.
Funding
Abstract
Serum free light chain (FLC) concentration is greatly affected by kidney function. Using a large prospective population-based cohort, we aimed to establish a reference interval for FLCs in persons with chronic kidney disease (CKD). A total of 75422 participants of the iStopMM study were screened with serum FLC, serum protein electrophoresis and immunofixation. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine. Central 99% reference intervals were determined, and 95% confidence intervals calculated. Included were 6461 (12%) participants with measured FLCs, eGFR < 60 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.